Genmab A+s

H. Lundbeck A/s

Genmab B.v.

Rob N De Jong

Paul Parren

Edward Norbert Van Den Brink

Janine Schuurman

Arnout F Gerritsen

Aran Frank Labrijn

Søren Christensen

Ibrahim John Malik

Frank Beurskens

Jeffrey B Stavenhagen

Jan Egebjerg

Lars Christian Biilmann Rønn

David Satijn

Esther Breij

Dennis Verzijl

Riemke Van Dijkhuizen Radersma

Sandra Verploegen

Jan Van De Winkel

Ole Baadsgaard

Tom Vink

Willem Karel Bleeker

David P E Satijn

Kristin Strumane

Maroeska Oudshoorn

Eva Ehrnrooth

Vibeke Miller Breinholt

Mischa Houtkamp

Rene Hoet

Marije Overdijk

Simone Oostindie

Richard Hibbert

Bart-Jan De Kreuk

Rene M A Hoet

Louise Koopman

Arjen Vlug

Annieck M Diks

Daniel Peeper

Henrik Jørn Ditzel

Rene MA Hoet

Ewald TJ Van Den Bremer

Kirstine Jacobsen

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

Antibody variant combinations and uses thereof

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Agent, uses and methods for treatment

The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

Method for producing a controlled mixture of two or more different antibodies

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

Polypeptide variants and uses thereof

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

Antibody variants and uses thereof

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

Dimeric protein with triple mutations

The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

Antibodies binding AXL

The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

Anti-sortilin antibodies, uses and methods for treatment

Growing community of inventors

Utrecht, Netherlands

Rob N De Jong